Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A post-market study evaluating the EMBOVAC Aspiration Catheter in acute ischemic stroke patients with confirmed intracranial large vessel occlusion.
The PERFECT Study is a prospective, multi-center, single arm, post-market clinical follow-up study.
The objective of this post-market clinical follow-up study is to assess the performance of the EMBOVAC Aspiration Catheter in the treatment of acute ischemic stroke in a real-world clinical setting.
The study will also report on clot characteristics and clinical outcomes.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| EMBOVAC Aspiration Catheter | Device | The EMBOVAC Aspiration catheter is used to treat acute ischemic stroke. The catheter can be used to facilitate introduction of diagnostic or therapeutic agents and is also intended for use in removal/aspiration of emboli and thrombi from selected blood vessels in the neuro vasculature. |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With Successful Revascularization | Successful revascularization was defined as achieving a final modified thrombolysis in cerebral infarction (mTICI) score of 2b or greater in target vessel. Revascularization was measured by an independent adjudicating imaging core laboratory and were reported using expanded treatment in cerebral infarction (eTICI) scale. eTICI was a 7-point grading system for determining response of thrombolytic therapy for ischemic stroke: 0=No reperfusion; 0 percent(%) filling of downstream territory; 1=Thrombus reduction without any reperfusion of distal arteries; 2a=Reperfusion in less than half (1-49%) of the territory; 2b=2b50 (reperfusion in [50-66%] of downstream territory) and 2b67 (reperfusion in (67-89%) of downstream territory); 2c=Reperfusion in [90-99%] of downstream territory; 3=Complete and 100% reperfusion where higher score indicated more successful revascularization. | Day 0 (post-procedure) |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With Successful Revascularization Without Rescue Therapy | Percentage of participants with successful revascularization without rescue therapy was reported. In this outcome measure, successful revascularization was defined as achieving a final mTICI score of 2b or greater in the target vessel as determined by the Independent Imaging Core Laboratory without use of rescue therapy. |
Not provided
Inclusion Criteria:
Exclusion Criteria
Not provided
Not provided
Not provided
Acute Ischemic Stroke patients with confirmed intracranial large vessel occlusion.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kyriakos Lobotesis | Imperial College Healthcare NHS Trust | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Asklepios Klinik Altona | Hamburg | Germany | ||||
| Imperial College Healthcare NHS Trust |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38609174 | Derived | Piano M, Jansen O, Marnat G, Gory B, Nordmeyer H, Eckert B, Pedicelli A, Cognard C, Loehr C, Zanoni M, Schaefer A, Macera A, Fiehler J, Doyle K, Lobotesis K. Prospective evaluation to characterize the real-world performance of the EMBOVAC aspiration catheter for neurothrombectomy: a post-market clinical follow-up trial. J Neurointerv Surg. 2025 Feb 14;17(3):254-260. doi: 10.1136/jnis-2023-021407. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | EMBOVAC Aspiration Catheter | Participants with acute ischemic stroke evaluated by the physician (in accordance with their institutional practice) were attempted with EMBOVAC aspiration catheter or aspiration procedure was performed on Day 0. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | EMBOVAC Aspiration Catheter | Participants with acute ischemic stroke evaluated by the physician (in accordance with their institutional practice) were attempted with EMBOVAC aspiration catheter or aspiration procedure was performed on Day 0. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Participants With Successful Revascularization | Successful revascularization was defined as achieving a final modified thrombolysis in cerebral infarction (mTICI) score of 2b or greater in target vessel. Revascularization was measured by an independent adjudicating imaging core laboratory and were reported using expanded treatment in cerebral infarction (eTICI) scale. eTICI was a 7-point grading system for determining response of thrombolytic therapy for ischemic stroke: 0=No reperfusion; 0 percent(%) filling of downstream territory; 1=Thrombus reduction without any reperfusion of distal arteries; 2a=Reperfusion in less than half (1-49%) of the territory; 2b=2b50 (reperfusion in [50-66%] of downstream territory) and 2b67 (reperfusion in (67-89%) of downstream territory); 2c=Reperfusion in [90-99%] of downstream territory; 3=Complete and 100% reperfusion where higher score indicated more successful revascularization. | The modified intent-to-treat (mITT) analysis set consisted of enrolled participants who received treatment (at least one pass; a pass was defined as use of aspiration followed by evaluation of revascularization with angiography) with the study device. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. | Posted | Number | 95% Confidence Interval | Percentage of participants | Day 0 (post-procedure) |
Serious adverse events and Other adverse events (Non-serious): Up to Day 90; for all-cause mortality: From Day 0 to end of the study (i.e., up to 21.3 months )
The safety analysis set consist of all enrolled participants in whom the treatment was attempted, defined by the advancement of the EMBOVAC Aspiration Catheter inside the participant.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | EMBOVAC Aspiration Catheter | Participants with acute ischemic stroke evaluated by the physician (in accordance with their institutional practice) were attempted with EMBOVAC aspiration catheter or aspiration procedure was performed on Day 0. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cerebral artery occlusion | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Haemorrhagic transformation stroke | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Cerenovus Clinical Research Director | CERENOVUS | 844-434-4210 | ClinicalTrialDisclosure@its.jnj.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Nov 5, 2021 | May 2, 2023 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jan 20, 2022 | May 2, 2023 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D000083242 | Ischemic Stroke |
| ID | Term |
|---|---|
| D020521 | Stroke |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood Clot / Thrombus
| Day 0 |
| Percentage of Participants With Complete Revascularization | Complete revascularization was defined as achieving a final mTICI score of 2c or greater in the target vessel as determined by the Independent Imaging Core Laboratory. Revascularization was measured by an independent adjudicating imaging core laboratory and were reported using expanded treatment in cerebral infarction(eTICI) scale. eTICI was a 6-point grading system for determining response of thrombolytic therapy for ischemic stroke:0=No reperfusion; 0 percent (%) filling of downstream territory;1=Thrombus reduction without any reperfusion of distal arteries;2a=Reperfusion in less than half (1-49%) of territory; 2b=2b50 (reperfusion in [50-66%] of downstream territory) and 2b67 (reperfusion in (67-89%) of downstream territory);2c=Reperfusion in [90-99%] of downstream territory;3=Complete and 100% reperfusion where higher score indicated successful revascularization. | Day 0 |
| Percentage of Participants With First Pass Effect Without Rescue Therapy | Percentage of participants with first pass effect without rescue therapy (mTICI score of 2c or greater after the first pass with the EMBOVAC Aspiration Catheter as determined by the Independent Imaging Core Laboratory) was reported. First pass effect was described as a complete revascularization obtained after a single device pass with no rescue therapy. | Day 0 |
| Percentage of Participants With Modified First Pass Effect | Percentage of participants with modified first pass effect was reported. Modified first pass effect was defined as mTICI of 2b or greater after the first pass with the EMBOVAC aspiration catheter as determined by the Independent Imaging Core Laboratory. | Day 0 |
| Time to Recanalization | Time (in minutes) to recanalization (reopening of a previously occluded passageway within a blood vessel) was defined as the procedure time from arterial puncture to recanalization (achievement of the first mTICI score >=2b as determined by the core laboratory) or visualization of final angiographic result if an mTICI score of 2b or greater was not achieved". | Day 0 |
| Percentage of Participants With Modified Rankin Scale (mRS) Scores 0 to 2 at Day 90 | Percentage of participants with mRS scores 0 to 2 at 90 days was reported. The mRS is a scale commonly used to measure the degree of disability or dependence in the daily activities in participants following stroke or other neurological event. It was a 7-point scale that ranged from 0 to 6 where 0=no symptoms at all; 1=no significant disability despite symptoms; 2=slight disability; 3=moderate disability; 4=moderately severe disability; 5=severe disability; 6=death. A lower number indicated lower disability. The mRS evaluation at 90 days was performed by an independent assessor. | at Day 90 |
| Percentage of Participants With Device Related Serious Adverse Events (SAEs) | SAE was any untoward medical occurrence that at any dose may result in death,life-threatening illness or injury, permanent impairment of body structure or body function including chronic diseases, in-patient or prolonged hospitalization, medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to body structure or body function, fetal distress, fetal death or congenital abnormality or birth defect including physical or mental impairment. Serious adverse device effect was adverse device effect that was resulted in any of consequences characteristic of SAE. Any device related serious adverse event associated with the use of EMBOVAC Aspiration Catheter (or cannot be ruled out as having caused the event) up to 90 days post index stroke procedure. Device relatedness was adjudicated by an independent Clinical Events Committee (CEC). | Up to Day 90 post procedure on Day 0 |
| Percentage of Participants With Symptomatic Intracerebral Hemorrhage (sICH) | Percentage of participants with sICH according to Heidelberg Bleeding Classification at 24 hours (hr) post procedure was reported. sICH:new intracranial hemorrhage detected by brain imaging (measured 24 hr post intervention) associated with any of item:>=4 points total National Institute of Health Stroke Scale (NIHSS:tool used by healthcare providers to objectively quantify impairment caused by stroke) at time of diagnosis compared to immediately before worsening; >=2 point in 1 NIHSS category. Rationale:to capture new hemorrhages that produced new neurological symptoms, making it clearly symptomatic but not causing worsening in original stroke territory; lead to intubation/hemicraniectomy/external ventricular drain placement or other major medical/surgical intervention or absence of alternative explanation for deterioration. Independent imaging core laboratory reviewed all 24 hr imaging to identify all ICH. Independent Clinical Events Committee judged ICH as symptomatic/asymptomatic. | 24 hours post procedure on Day 0 |
| Change From Baseline in National Institutes of Health Stroke Scale (NIHSS) Total Score at 24 Hours Post-procedure | Change from baseline in NIHSS total Score at 24 hours post procedure was reported. NIHSS is an assessment which objectively quantifies the impairment caused by stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, 0=normal function in that specific ability, while a higher score (4)=some level of impairment. The individual scores from each item are summed in order to calculate a participant's total NIHSS score. The participant's total NIHSS score ranges from 0 (minimum) - 42 (maximum). Score 0 (no stroke symptoms); 1 - 4 (Minor stroke); 5-15 (Moderate stroke); 16-20 (Moderate to severe stroke); and 21-42 (Severe stroke). | Baseline (Day 0, before procedure) up to 24 hours post procedure on Day 0 |
| Number of Participants With All-Cause Mortality Thorugh 90 Days | Number of participants with all-cause mortality through 90 days post procedure was reported. All-cause mortality included all deaths of participants due to any cause. Participants without events were censored at the date of last contact in the study. | 90 days post procedure on Day 0 |
| London |
| United Kingdom |
| Years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
|
|
|
| Secondary | Percentage of Participants With Successful Revascularization Without Rescue Therapy | Percentage of participants with successful revascularization without rescue therapy was reported. In this outcome measure, successful revascularization was defined as achieving a final mTICI score of 2b or greater in the target vessel as determined by the Independent Imaging Core Laboratory without use of rescue therapy. | The mITT analysis set consisted of enrolled participants who received treatment (at least one pass; a pass was defined as use of aspiration followed by evaluation of revascularization with angiography) with the study device. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. | Posted | Number | 95% Confidence Interval | Percentage of participants | Day 0 |
|
|
|
| Secondary | Percentage of Participants With Complete Revascularization | Complete revascularization was defined as achieving a final mTICI score of 2c or greater in the target vessel as determined by the Independent Imaging Core Laboratory. Revascularization was measured by an independent adjudicating imaging core laboratory and were reported using expanded treatment in cerebral infarction(eTICI) scale. eTICI was a 6-point grading system for determining response of thrombolytic therapy for ischemic stroke:0=No reperfusion; 0 percent (%) filling of downstream territory;1=Thrombus reduction without any reperfusion of distal arteries;2a=Reperfusion in less than half (1-49%) of territory; 2b=2b50 (reperfusion in [50-66%] of downstream territory) and 2b67 (reperfusion in (67-89%) of downstream territory);2c=Reperfusion in [90-99%] of downstream territory;3=Complete and 100% reperfusion where higher score indicated successful revascularization. | The mITT analysis set consisted of enrolled participants who received treatment (at least one pass; a pass was defined as use of aspiration followed by evaluation of revascularization with angiography) with the study device. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. | Posted | Number | 95% Confidence Interval | Percentage of participants | Day 0 |
|
|
|
| Secondary | Percentage of Participants With First Pass Effect Without Rescue Therapy | Percentage of participants with first pass effect without rescue therapy (mTICI score of 2c or greater after the first pass with the EMBOVAC Aspiration Catheter as determined by the Independent Imaging Core Laboratory) was reported. First pass effect was described as a complete revascularization obtained after a single device pass with no rescue therapy. | The mITT analysis set consisted of enrolled participants who received treatment (at least one pass; a pass was defined as use of aspiration followed by evaluation of revascularization with angiography) with the study device. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. | Posted | Number | 95% Confidence Interval | Percentage of participants | Day 0 |
|
|
|
| Secondary | Percentage of Participants With Modified First Pass Effect | Percentage of participants with modified first pass effect was reported. Modified first pass effect was defined as mTICI of 2b or greater after the first pass with the EMBOVAC aspiration catheter as determined by the Independent Imaging Core Laboratory. | The mITT analysis set consisted of enrolled participants who received treatment (at least one pass; a pass was defined as use of aspiration followed by evaluation of revascularization with angiography) with the study device. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. | Posted | Number | 95% Confidence Interval | Percentage of participants | Day 0 |
|
|
|
| Secondary | Time to Recanalization | Time (in minutes) to recanalization (reopening of a previously occluded passageway within a blood vessel) was defined as the procedure time from arterial puncture to recanalization (achievement of the first mTICI score >=2b as determined by the core laboratory) or visualization of final angiographic result if an mTICI score of 2b or greater was not achieved". | The mITT analysis set consisted of enrolled participants who received treatment (at least one pass; a pass was defined as use of aspiration followed by evaluation of revascularization with angiography) with the study device. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. | Posted | Mean | Standard Deviation | Minutes | Day 0 |
|
|
|
| Secondary | Percentage of Participants With Modified Rankin Scale (mRS) Scores 0 to 2 at Day 90 | Percentage of participants with mRS scores 0 to 2 at 90 days was reported. The mRS is a scale commonly used to measure the degree of disability or dependence in the daily activities in participants following stroke or other neurological event. It was a 7-point scale that ranged from 0 to 6 where 0=no symptoms at all; 1=no significant disability despite symptoms; 2=slight disability; 3=moderate disability; 4=moderately severe disability; 5=severe disability; 6=death. A lower number indicated lower disability. The mRS evaluation at 90 days was performed by an independent assessor. | The mITT analysis set consisted of enrolled participants who received treatment (at least one pass; a pass was defined as use of aspiration followed by evaluation of revascularization with angiography) with the study device. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. | Posted | Number | 95% Confidence Interval | Percentage of participants | at Day 90 |
|
|
|
| Secondary | Percentage of Participants With Device Related Serious Adverse Events (SAEs) | SAE was any untoward medical occurrence that at any dose may result in death,life-threatening illness or injury, permanent impairment of body structure or body function including chronic diseases, in-patient or prolonged hospitalization, medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to body structure or body function, fetal distress, fetal death or congenital abnormality or birth defect including physical or mental impairment. Serious adverse device effect was adverse device effect that was resulted in any of consequences characteristic of SAE. Any device related serious adverse event associated with the use of EMBOVAC Aspiration Catheter (or cannot be ruled out as having caused the event) up to 90 days post index stroke procedure. Device relatedness was adjudicated by an independent Clinical Events Committee (CEC). | The safety analysis set consisted of all enrolled participants in whom the procedure was attempted, defined by the advancement of the EMBOVAC Aspiration Catheter inside the participant. | Posted | Number | 95% Confidence Interval | Percentage of participants | Up to Day 90 post procedure on Day 0 |
|
|
|
| Secondary | Percentage of Participants With Symptomatic Intracerebral Hemorrhage (sICH) | Percentage of participants with sICH according to Heidelberg Bleeding Classification at 24 hours (hr) post procedure was reported. sICH:new intracranial hemorrhage detected by brain imaging (measured 24 hr post intervention) associated with any of item:>=4 points total National Institute of Health Stroke Scale (NIHSS:tool used by healthcare providers to objectively quantify impairment caused by stroke) at time of diagnosis compared to immediately before worsening; >=2 point in 1 NIHSS category. Rationale:to capture new hemorrhages that produced new neurological symptoms, making it clearly symptomatic but not causing worsening in original stroke territory; lead to intubation/hemicraniectomy/external ventricular drain placement or other major medical/surgical intervention or absence of alternative explanation for deterioration. Independent imaging core laboratory reviewed all 24 hr imaging to identify all ICH. Independent Clinical Events Committee judged ICH as symptomatic/asymptomatic. | The safety analysis set consisted of all enrolled participants in whom the procedure was attempted, defined by the advancement of the EMBOVAC Aspiration Catheter inside of the participant. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. | Posted | Number | 95% Confidence Interval | Percentage of participants | 24 hours post procedure on Day 0 |
|
|
|
| Secondary | Change From Baseline in National Institutes of Health Stroke Scale (NIHSS) Total Score at 24 Hours Post-procedure | Change from baseline in NIHSS total Score at 24 hours post procedure was reported. NIHSS is an assessment which objectively quantifies the impairment caused by stroke. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, 0=normal function in that specific ability, while a higher score (4)=some level of impairment. The individual scores from each item are summed in order to calculate a participant's total NIHSS score. The participant's total NIHSS score ranges from 0 (minimum) - 42 (maximum). Score 0 (no stroke symptoms); 1 - 4 (Minor stroke); 5-15 (Moderate stroke); 16-20 (Moderate to severe stroke); and 21-42 (Severe stroke). | The safety analysis set consisted of all enrolled participants in whom the procedure was attempted, defined by the advancement of the EMBOVAC Aspiration Catheter inside of the participant. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this outcome measure. | Posted | Mean | Standard Deviation | Scores on a scale | Baseline (Day 0, before procedure) up to 24 hours post procedure on Day 0 |
|
|
|
| Secondary | Number of Participants With All-Cause Mortality Thorugh 90 Days | Number of participants with all-cause mortality through 90 days post procedure was reported. All-cause mortality included all deaths of participants due to any cause. Participants without events were censored at the date of last contact in the study. | The safety analysis set consisted of all enrolled participants in whom the procedure was attempted, defined by the advancement of the EMBOVAC Aspiration Catheter inside of the participant. | Posted | Count of Participants | Participants | 90 days post procedure on Day 0 |
|
|
|
| 14 |
| 102 |
| 26 |
| 102 |
| 17 |
| 102 |
| Cerebral haemorrhage | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
|
| Haemorrhage intracranial | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
|
| Haemorrhagic transformation stroke | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
|
| Brain oedema | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
|
| Stroke in evolution | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
|
| Pneumonia | Infections and infestations | MedDRA 23.0 | Systematic Assessment |
|
| Sepsis | Infections and infestations | MedDRA 23.0 | Systematic Assessment |
|
| Endocarditis | Infections and infestations | MedDRA 23.0 | Systematic Assessment |
|
| Urosepsis | Infections and infestations | MedDRA 23.0 | Systematic Assessment |
|
| Atrial fibrillation | Cardiac disorders | MedDRA 23.0 | Systematic Assessment |
|
| Atrioventricular block | Cardiac disorders | MedDRA 23.0 | Systematic Assessment |
|
| Cardiac arrest | Cardiac disorders | MedDRA 23.0 | Systematic Assessment |
|
| Sinus node dysfunction | Cardiac disorders | MedDRA 23.0 | Systematic Assessment |
|
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment |
|
| Dyspnea | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment |
|
| Intraoperative cerebral artery occlusion | Injury, poisoning and procedural complications | MedDRA 23.0 | Systematic Assessment |
|
| Vascular access site occlusion | Injury, poisoning and procedural complications | MedDRA 23.0 | Systematic Assessment |
|
| Vascular access site pseudoaneurysm | Injury, poisoning and procedural complications | MedDRA 23.0 | Systematic Assessment |
|
| Diverticulum intestinal | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment |
|
| Pharyngo-oesophageal diverticulum | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment |
|
| Death | General disorders | MedDRA 23.0 | Systematic Assessment |
|
| Hyponatraemia | Metabolism and nutrition disorders | MedDRA 23.0 | Systematic Assessment |
|
| Vulval cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA 23.0 | Systematic Assessment |
|
| Subarachnoid haemorrhage | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
|
| Cerebral artery perforation | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
|
| Cerebral microhaemorrhage | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
|
| Intraventricular haemorrhage | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
|
| Migraine | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
|
| Syncope | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
|
| Air embolism | Vascular disorders | MedDRA 23.0 | Systematic Assessment |
|
| Hypotension | Vascular disorders | MedDRA 23.0 | Systematic Assessment |
|
| Vascular access site haematoma | Injury, poisoning and procedural complications | MedDRA 23.0 | Systematic Assessment |
|
| Organic brain syndrome | Psychiatric disorders | MedDRA 23.0 | Systematic Assessment |
|
| Vasospasm | Vascular disorders | MedDRA 23.0 | Systematic Assessment |
|
Draft abstracts, manuscripts, and materials for presentation at scientific meetings must be sent to the sponsor at least 60 working days prior to abstract or other relevant submission deadlines. Authorship of publications resulting from this study was based on generally accepted criteria for major medical journals.
| D009422 |
| Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |